The present invention relates to extracellular vesicles which are derived from immunoregulatory macrophage cells. The vesicles exert immunoregulatory, angiogenic and tissue regenerative properties and are thus useful for the treatment of different diseases and conditions. In a further aspect, the invention relates to a pharmaceutical composition comprising the extracellular vesicles of the invention. In a still further aspect, the invention relates to the use of the extracellular vesicles or a pharmaceutical composition comprising such vesicles in medicine. In a still further aspect, the invention relates to the use of the extracellular vesicles or a pharmaceutical composition comprising such vesicles for treating or preventing immunological and non-immunological diseases and conditions, including autoimmune diseases, inflammatory diseases, hypersensitivity reactions, transplant rejection and micro- or macroangiopathies of the lower limbs. The invention also provides a process for preparing the macrophage- derived extracellular vesicles from blood monocytes. Finally, the invention provides a process for preparing immunoregulatory T cells which makes use of the extracellular vesicles.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
2.
NEW IMMUNOREGULATORY CELLS AND METHODS FOR THEIR PRODUCTION
The present invention relates to novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions. The cells are characterized by a specific marker and activity pattern which distinguishes them from other cells. The invention also provides a process for preparing the immunoregulatory macrophage cells from blood monocytes. In a still further aspect, the invention relates to a pharmaceutical composition comprising the immunoregulatory macrophage cells of the invention or a sub-cellular fraction thereof. A process for preparing a sub-cellular fraction of an immunoregulatory macrophage cell of the invention is also provided.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
The present invention relates to the use of immunoregulatory macrophages for treating diseases that are associated with pathological changes of the blood vessels. The present invention particularly relates to the use of immunoregulatory macrophages for treating micro- and macroangiopathies of the lower limbs. The invention furthermore relates to the use of immunoregulatory macrophages for promoting tissue remodelling to facilitate wound healing. Pharmaceutical compositions for use in the recited treatments are also disclosed which comprise the immunoregulatory macrophages.
The present invention relates to the use of immunoregulatory macrophages for treating diseases that are associated with pathological changes of the blood vessels. The present invention particularly relates to the use of immunoregulatory macrophages for treating micro- and macroangiopathies of the lower limbs. The invention furthermore relates to the use of immunoregulatory macrophages for promoting tissue remodelling to facilitate wound healing. Pharmaceutical compositions for use in the recited treatments are also disclosed which comprise the immunoregulatory macrophages.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a method for detecting regulatory T cells (Tregs) in the blood of a subject by use of a novel marker. The method includes the detection of at least one commonly known marker for regulatory T cells (Tregs) in combination with the detection of the marker BTNL8. The method allows the reliable detection and quantification of different Treg populations which are involved in important immunological functions, such as immunosuppression and maintenance of immune tolerance. The invention also provides a method for monitoring the treatment of a subject suffering from an immunological disease or condition which makes use of the novel marker. The invention also relates to the use of a means that allow the specific detection of BTNL8 for detecting Tregs. Kits comprising detection means for detecting commonly known markers of Tregs along with BTNL8 are also provided.
The present invention relates to the use of immunoregulatory macrophages for treating diseases that are associated with pathological changes of the blood vessels. The present invention particularly relates to the use of immunoregulatory macrophages for treating micro-and macroangiopathies of the lower limbs. The invention furthermore relates to the use of immunoregulatory macrophages for promoting tissue remodelling to facilitate wound healing.Pharmaceutical compositions for use in the recited treatments are also disclosed which comprise the immunoregulatory macrophages.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
The present invention relates to a method for detecting regulatory T cells (Tregs) in the blood of a subject by use of a novel marker. The method includes the detection of at least one commonly known marker for regulatory T cells (Tregs) in combination with the detection of the marker BTNL8. The method allows the reliable detection and quantification of different Treg populations which are involved in important immunological functions, such as immunosuppression and maintenance of immune tolerance. The invention also provides a method for monitoring the treatment of a subject suffering from an immunological disease or condition which makes use of the novel marker. The invention also relates to the use of a means that allow the specific detection of BTNL8 for detecting Tregs. Kits comprising detection means for detecting commonly known markers of Tregs along with BTNL8 are also provided.
patents
